CKM syndrome is a framework developed to describe the biological links among obesity, diabetes, high blood pressure, cardiovascular disease and chronic kidney disease. Rather than treating these conditions as isolated problems, the framework views them as interconnected consequences of metabolic stress, vascular damage, inflammation and declining organ function. In the operational classification used by the researchers, stages 2–3 encompass people with metabolic risk factors, kidney abnormalities or subclinical cardiovascular disease, while stage 4 represents established cardiovascular disease, kidney disease or both in the presence of metabolic risk. This distinction matters because patients with advanced CKM syndrome often have a high risk of hospitalization, progressive loss of kidney function and death, while also being more difficult to include in conventional trials. By mapping existing trial populations onto CKM stages, the investigators sought to test whether the benefits of SGLT2 inhibition extended across this clinically connected spectrum.

SGLT2 inhibitors were first developed as glucose-lowering medicines for type 2 diabetes, but their effects extend beyond blood sugar control. The drugs block the SGLT2 protein in the proximal tubule of the kidney, where much of the glucose and sodium filtered from the blood is normally reclaimed. Inhibition increases urinary glucose excretion and causes a modest increase in sodium loss. That change alters signaling between the kidney’s filtration apparatus and the renin–angiotensin system, helping to reduce pressure inside the glomeruli, the microscopic structures that filter blood. The medicines also produce a mild diuretic and natriuretic effect, reducing fluid congestion that can strain the heart. Researchers believe these mechanisms, together with changes in renal oxygen demand, vascular function and cardiac metabolism, help explain why the drugs can benefit patients with or without diabetes.

Sun, Guo and their colleagues searched PubMed/MEDLINE, Web of Science, Embase and the Cochrane Central Register of Controlled Trials for randomized controlled trials available through 25 February 2026. They included trials comparing an SGLT2 inhibitor with placebo or usual care and grouped trial populations, or mutually exclusive subgroups reported within trials, according to the CKM stage framework. Nineteen reports derived from 11 parent randomized trials met the criteria. A total of 18,547 participants were assigned to the CKM stages 2–3 group, while 54,673 were classified as stage 4. The researchers pooled six time-to-event outcomes using restricted maximum likelihood random-effects models. This statistical approach allows for the possibility that the true treatment effect differs somewhat among studies rather than assuming that all trials are estimating one identical effect.

The clearest signals involved heart failure and kidney disease. For the composite heart-failure outcome, the hazard ratio was 0.80 in CKM stages 2–3, with a 95 percent confidence interval of 0.68 to 0.93, and 0.77 in stage 4, with a confidence interval of 0.73 to 0.81. A hazard ratio below 1 indicates fewer events in the SGLT2 inhibitor group; these estimates correspond roughly to relative reductions of 20 percent and 23 percent, respectively. For hospitalization for heart failure, the hazard ratio was 0.61 in stages 2–3 and 0.71 in stage 4, equivalent to approximate relative reductions of 39 percent and 29 percent. Kidney outcomes also favored treatment, with hazard ratios of 0.61 and 0.64 in the two groups. These findings are consistent with the drugs’ established ability to slow clinically important kidney deterioration and reduce heart-failure events in several different patient populations.

The statistical comparisons did not show that the apparent differences between groups were significant. The P value for the comparison of composite heart-failure outcomes between CKM stages 2–3 and stage 4 was 0.65. For heart-failure hospitalization it was 0.24, and for kidney outcomes it was 0.64. In practical terms, the available data did not demonstrate that one CKM group gained more or less benefit than the other. But a non-significant difference is not the same as proof of identical effects. The stages 2–3 analysis was based on only four estimates, creating wider confidence intervals and greater uncertainty. Stage 4 estimates were generally more precise because the group included more participants and more events. The researchers therefore describe the results as evidence of benefit in both groups, not as definitive evidence that the magnitude of benefit is equivalent.

The analysis also examined major adverse cardiovascular events, commonly known as MACE, and all-cause mortality. Estimates for MACE and mortality in CKM stage 4 were more precise, reflecting the larger evidence base in that category, but the source material does not report a single statistically significant stage-based difference for these outcomes. The researchers registered five main outcomes rather than designating one primary endpoint, while all-cause mortality was registered as a secondary outcome. That distinction is important because a study evaluating several outcomes can produce a complex pattern of results, and individual findings may vary in certainty. An exploratory Egger test for all-cause mortality produced a P value of 0.025, raising the possibility of small-study effects or publication bias. Such tests are difficult to interpret when the number of contributing estimates is limited, so the result is a warning signal rather than evidence that the overall mortality conclusion is invalid.

To test whether the findings depended on particular analytical decisions, the investigators performed prespecified sensitivity analyses. They examined alternative statistical models, removed the SOLOIST-WHF trial because a selected efficacy result was judged to have a high risk of bias, tested different definitions of kidney endpoints and assessed whether any single study disproportionately influenced the results. They also investigated possible small-study effects. The principal heart-failure and kidney findings remained stable across these checks, strengthening confidence that the observed pattern was not created by one trial or one endpoint definition. Nevertheless, meta-analysis inherits limitations from the studies it combines. Trial participants may differ in baseline kidney function, diabetes status, heart-failure phenotype, medication use and follow-up duration, while operationally assigning populations to CKM stages cannot fully reproduce the complexity of individual patients.

The findings arrive as SGLT2 inhibitors are increasingly used across cardiology, nephrology and endocrinology, including in patients with heart failure with reduced, mildly reduced or preserved ejection fraction and in people with chronic kidney disease. Their apparent benefits across these specialties have helped shift the drugs from narrowly targeted diabetes treatments to therapies with broader cardiorenal applications. The new review reinforces that cross-disciplinary picture: patients at different points along the CKM pathway experienced fewer heart-failure and kidney events when receiving an SGLT2 inhibitor than when receiving placebo or usual care. Still, treatment decisions must account for kidney function, volume status, genital and urinary infections, ketoacidosis risk and other individual factors. The authors’ central conclusion is appropriately cautious: SGLT2 inhibitors favored heart-failure and kidney outcomes in both CKM stage groups, but more evidence—especially in earlier-stage CKM disease—is needed to determine how treatment effects compare across the full continuum.

Subject of Research: Cardiorenal effects of SGLT2 inhibitors across cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4

Article Title: SGLT2 inhibitors and cardiorenal outcomes across operationally mapped cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4: a systematic review and meta-analysis

Article References: Sun, S., Guo, Y., Wu, H. et al. SGLT2 inhibitors and cardiorenal outcomes across operationally mapped cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4: a systematic review and meta-analysis. BMC Endocrine Disorders (2026). Original research article

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02478-6

Keywords: SGLT2 inhibitors, cardiovascular-kidney-metabolic syndrome, heart failure, chronic kidney disease, cardiorenal outcomes, randomized controlled trials, systematic review, meta-analysis

At the heart of the research lies the urgent need for effective assessment tools to evaluate symptom severity in older patients, particularly those who face overlapping chronic diseases such as diabetes, hypertension, and heart disease. These cardiometabolic conditions are not merely additive; they interact in ways that complicate the clinical picture, necessitating a more sophisticated approach to symptom management. The development of a specific scale for symptom severity stands to revolutionize the clinician’s toolkit in tailoring interventions that address the multifaceted nature of these health issues.

The study’s findings are based on rigorous psychometric testing, ensuring that the newly developed scale is both reliable and valid. Reliability refers to the consistency of the scale across different assessments, while validity speaks to its ability to measure what it is intended to measure. Through extensive statistical analyses, Eren and Sert have demonstrated that their scale not only meets established psychometric standards but also resonates with the lived experiences of older patients. This has significant implications for both diagnostic accuracy and treatment effectiveness.

Importantly, the research highlights the nuances involved in symptom reporting among the elderly. Older adults may exhibit a unique symptom burden that is often underappreciated in clinical settings. Factors such as cognitive decline, medication polypharmacy, and psychosocial stressors contribute to a complex symptomatology that demands a specialized scale. By engaging with older adults in the development phase of this tool, researchers have ensured that it encompasses a broader spectrum of patient experiences and captures the subtleties of their conditions.

The methodology employed in this study reflects contemporary best practices in health research. Eren and Sert adopted a mixed-methods approach, combining qualitative interviews with quantitative surveys to ensure a comprehensive understanding of symptom severity. This fusion of data types allows for a deeper insight into how cardiometabolic multimorbidity manifests in older adults, highlighting symptoms that may not otherwise be prioritized in traditional clinical assessments.

Psychometric testing involved an iterative process of refinement, where initial versions of the scale underwent testing and feedback loops, leading to improved iterations. This process underscores the importance of adaptability and responsiveness in health instrument development. The final version of the Symptom Severity Scale is thus not only a scientific instrument but also a product of collaboration between researchers, healthcare professionals, and patients.

Empirical results from the study provide compelling evidence for the scale’s efficacy. Significant correlations were observed between the severity scores obtained using the new scale and established measures of health-related quality of life. This relationship speaks to the scale’s potential to identify patients at risk for poorer outcomes, thus facilitating timely interventions that can significantly enhance quality of life among the elderly.

Acknowledging the diversity of older populations, the researchers also assessed the scale’s applicability across various demographic groups. This aspect of the study addresses a critical gap in existing assessment tools that often fail to account for cultural, social, and economic differences that can influence health perceptions and symptom reporting. Eren and Sert’s work encourages a more personalized approach to healthcare that respects and incorporates these variances.

In addition to clinical implications, the research carries significant ramifications for public health policy. As the global population ages, addressing the needs of older adults with multimorbidity becomes essential in the design of health systems. The establishment of standardized symptom severity assessments can lead to improved health outcomes and a more efficient allocation of healthcare resources. By advocating for policies that integrate tools like the Symptom Severity Scale, policymakers can ensure that older adults receive care that is both comprehensive and contextually relevant.

Critically, the research contributes to a growing body of literature that calls for a paradigm shift in how healthcare processes are organized for the aging population. Rather than viewing older adults solely through the lens of individual disease processes, there is a pressing need to embrace a holistic approach that recognizes the interconnectedness of multiple health conditions. Such a shift could herald a new era in geriatric healthcare delivery, emphasizing comprehensive assessments and tailored treatment plans.

The potential for the Symptom Severity Scale extends beyond individual patient assessments; it may play a pivotal role in clinical trials aimed at developing new interventions for cardiometabolic multimorbidity. By utilizing this scale, researchers can more accurately measure treatment effects and better understand the patient population’s response to various therapies. This is particularly crucial given the increasing prevalence of multimorbidity, which complicates treatment pathways and poses significant challenges in clinical research.

As healthcare providers look to incorporate this scale into routine practice, training and education will be vital. Ensuring that clinicians are adept at utilizing this tool will maximize its effectiveness and enhance the overall quality of care for older patients. Furthermore, ongoing research is necessary to refine and expand the scale, ensuring it remains relevant as new findings emerge in geriatric medicine and public health.

In sum, the development and psychometric testing of the Symptom Severity Scale by Eren and Sert signifies a pivotal advancement in addressing the needs of older adults with cardiometabolic multimorbidity. This innovative assessment tool not only enhances clinical understanding but also advocates for a more empathetic and multifaceted approach to geriatric care. As research continues to evolve, the hope is that tools like this will empower both healthcare providers and patients towards more meaningful health outcomes.

Such significant strides in geriatric research underscore the essential work being done to better understand and serve one of society’s most vulnerable populations—a demographic that will continue to grow in prominence as the global population ages.

Subject of Research: Development of the Symptom Severity Scale for older patients with cardiometabolic multimorbidity.

Article Title: Development and psychometric testing of symptom severity scale in older patients with cardiometabolic multimorbidity.

Article References:

Gulbahar Eren, M., Sert, H. Development and psychometric testing of symptom severity scale in older patients with cardiometabolic multimorbidity.
BMC Geriatr 25, 771 (2025). https://doi.org/10.1186/s12877-025-06370-1

Image Credits: AI Generated

DOI: 10.1186/s12877-025-06370-1

Keywords: symptom severity, cardiometabolic multimorbidity, geriatric patients, psychometric testing, health assessment tools.